Overview Levetiracetam 1000 mg Under Fasting Conditions Status: Completed Trial end date: 2007-01-01 Target enrollment: Participant gender: Summary THe objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fasting conditions. Phase: Phase 1 Details Lead Sponsor: Teva Pharmaceuticals USATreatments: EtiracetamLevetiracetamPiracetam